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httpcense.Abstract Background: The risk of venous thromboembolism (VTE) is equally high in medical
patients admitted to the hospital and those treated in the surgery wards. Patients who are immobi-
lized due to heart failure, severe respiratory disease, cerebrovascular stroke and cancer are at a high
risk of venous thrombosis.
Aim of the work: The aim of the study was to assess the impact of different respiratory insults on
blood coagulation for early detection and prevention of thrombosis to open the way for thrombo-
prophylaxis in such cases.
Patients and methods: The study included 25 apparently normal healthy control subjects and 141
patients with different respiratory disorders. All patients were subjected to full medical history tak-
ing, full clinical examination, and radiological evaluation. Computed tomography (CT) pulmonary
angiography was done for all cases and lower limb duplex ultrasonography for all patients, at day 1
and day 5 of admission. The following coagulation markers were evaluated for all patients at day 1,
2,3,4, and 5 of admission including: Soluble ﬁbrin complex, D dimer, thrombin antithrombin com-
plex, antithrombin, protein C, protein S, and ﬁbrinogen.
Results: It was found that, the mean values of soluble ﬁbrin complex, D dimer and thrombin
antithrombin complex were higher in patients with positive duplex ultrasonograghy and positive
CT angiography than patients with negative duplex ultrasonograghy and CT angiography and the
difference was statistically highly signiﬁcant. The higher mean values for soluble ﬁbrin complex
was on the third day of admission, while the higher mean values for D dimer, thrombin antithrombin01747101.
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332 H.M. Abd Elsalam et al.complex and ﬁbrinogen were on the ﬁfth day. Whereas, there are no detectable variations in levels of
antithrombin, protein C and protein S on all 5 days there were highly statistically signiﬁcant differ-
ences in soluble ﬁbrin complex, D dimer and ﬁbrinogen levels between all disease groups and the con-
trol subjects. The mean values of soluble ﬁbrin complex, D dimer, thrombin antithrombin complex
and ﬁbrinogen were higher in severe COPD patients than in moderate COPD patients and the dif-
ference was statistically signiﬁcant while there was no statistically signiﬁcant difference in coagula-
tion marker levels between moderate and severe asthmatic patients and also, between
bronchogenic carcinoma and mesothelioma patients.
Conclusions: Estimation of soluble ﬁbrin complex, D dimer, thrombin antithrombin complex and
ﬁbrinogen may be useful for early identiﬁcation of the prethrombotic state which may help to pre-
vent the onset of thrombotic disorders and thereby improve the outcome of various respiratory dis-
eases. Common respiratory disorders especially, COPD exacerbation, pneumonia, interstitial
pulmonary ﬁbrosis, and lung cancer are considered to be hypercoagulable states which carry high
risks for the development of venous thromboembolism.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Although numerous studies about hemostatic biomarkers
have been performed in patients suspected of deep vein
thrombosis (DVT) or pulmonary embolism (PE), no data
are available on the level of such hemostatic markers in
non selected medical inpatients without any suspicion of
acute venous thrombosis [1]. Because they induce venous
stasis and inﬂammatory state, most acute medical diseases
are considered as being associated with an increased risk of
venous thrombo embolism (VTE) [2].
A prethrombotic state may be deﬁned as a condition
characterized by an imbalance in hemostasis with a tendency
for hyper-coagulability, due to pathological activation of the
enzymes of the coagulation cascade, but without clinical signs
of thrombosis or evidence of ﬁbrin deposition. Hypercoagula-
ble states can be classiﬁed into two broad categories: congenital
and acquired. The former are generally inherited normalities of
hemostasis clearly identiﬁed, while acquired hypercoagulable
states include clinical conditions associated with an increased
risk of thrombosis in which the exact pathophysiologic mecha-
nism remains unclear [3].
The importance of detecting these prethrombotic states
deals with the possibility to diminish the thrombotic tendency
by treating or eliminating the responsible factors. Advances in
our knowledge of the biochemistry of the hemostatic mecha-
nism have allowed the development of sensitive and speciﬁc
assays to detect activation of coagulation and ﬁbrinolysis
in vivo [4].
The frequency of PE increased signiﬁcantly as the D-dimer
level increased in acute exacerbation of COPD [5]. Interstitial
pulmonary ﬁbrosis (IPF) may be a hypercoaguable condition
and that components of the coagulation cascade are either
directly involved in or activated by ﬁbrosis-producing machin-
ery [6].
The elevated D-dimer level in patients with community
acquired pneumonia was associated with radiologic pneumonia
extension and poor outcome. Patients with lung cancer carry a
higher risk for developing venous thrombo-embolism. High
elevated plasma D-dimer concentrations in such cases were
associated with poor prognosis [7].
So, the aim of the study was to assess the impact of differ-
ent respiratory insults on blood coagulation for early detectionand prevention of thrombosis to open the way for thrombo-
prophylaxis in such cases.
Patients and methods
Study design
This study was carried out at chest department, respiratory
ICU and clinical pathology department of Zagazig University
Hospitals in the period from October 2010 to January 2012.
This study was conducted on 166 subjects, who were classiﬁed
into two groups:-
(I) Control group: included 25 apparently normal healthy
persons, 15 males and 10 females, their ages ranged from
23 to 46 years old with a mean of 35.8 ± 6.76 years.
(II) Patient group: included 141 patients with different respi-
ratory disorders, 37 males and 104 females, their ages
ranged from 33 to 65 years old with a mean of
52.3 ± 7.9 years. Those patients were subdivided
according to their pathological diagnosis into:-
- (21) patients with exacerbated bronchial asthma (16)
patients non mechanically ventilated and ﬁve mechan-
ically ventilated patients.
- (38) patients with exacerbated chronic obstructive
pulmonary disease (COPD) patients (25) patients
non mechanically ventilated and 13 mechanically
ventilated patients.
- (26) patients with acute exacerbation of interstitial
pulmonary ﬁbrosis. (IPF) (22) patients non mechani-
cally ventilated and four mechanically ventilated
patients.
- (31) patients with pneumonia (23) patients non
mechanically ventilated and eight mechanically
ventilated patients.
- (15) patients with lung cancer and (10) patients with
malignant mesothelioma.Exclusion criteria
Patients who have had diabetes mellitus, hepatic disorder, deep
vein thrombosis (DVT), and suspect pulmonary embolism
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dimer and duplex at time of admission), disseminated
intravascular coagulation (DIC), acute myocardial infarction
(AMI) and thrombotic thrombocytopenic purpura were
excluded from the study as, ﬁbrin-related markers such as
D-dimer, and soluble ﬁbrin complex (SFC) were reported to
be elevated in such diseases [8].
Patients who have had anticoagulant therapy were also
excluded from the study as the plasma levels of thrombin
antithrombin complex (TAT), D-dimer, antithrombin (AT)
and soluble ﬁbrin complex were affected. [9].Methods
All patients were subjected to the following:-
(1) Full medical history taking stressing on smoking habit,
occupational exposure, drug intake, duration of illness
and history of any other diseases.
(2) Full clinical examination General examination.
 Local chest examination.
(3) Radiological evaluation
(a) Plain chest ﬁlms (postero-anterior and lateral views)
(done for all cases).
(b) High resolution CT (22 cases).
(c) Conventional chest CT (35 cases) and CT guided
biopsy when indicated (25 cases).
Percutaneous transthoracic ﬁne needle aspiration biopsy
(TTNA) was done under CT guidance from suspected
peripheral pulmonary lesions by using spinal needle gauge 22
according to the method of Hideo and Nobuo [10].
(d) CT pulmonary angiography was done for all cases
(141 cases).
(e) Lower limb duplex ultrasonography for all patients,
at day 1, and at day 5 of admission.
Compression ultrasonography (Prisma Diasonics, Les Ulis,
France) with superﬁcial probe (7.5 MHz) was used for DVT
assessment. This device currently incorporates color Doppler
ﬂow with a B-mode image of vein projected either longitudi-
nally or transversely [11].Technique of duplex ultrasonography
Compression ultrasound with venous imaging (real- time B-
mode) was done utilizing a combination of gray scale duplex
and color doppler imaging to evaluate the deep venous system
of both lower limbs. The compression technique was used,
beginning at the inguinal ligament, and the common femoral
vein and great saphenous vein were evaluated, then the super-
ﬁcial femoral vein, which is a part of the deep venous system,
was evaluated, the deep femoral vein was evaluated at the
bifurcation of common femoral vein, then popliteal and calf
veins were evaluated [12].Color imaging was used to better evaluate the venous blood
ﬂow and this is especially useful for non-occlusive thrombi and
for calf vein evaluation in obese patients.
Criteria for the diagnosis of acute DVT
- Non-compressibility of the vein, this is the most reliable
sign of acute DVT.
- Echogenic thrombus within the vein lumen.
- Venous distention.
- Complete absence of color Doppler signal from the vein
lumen [13]
(4) Pulmonary function tests
These tests were done for 41 cases, (COPD, asthma and IPF
patients). These were carried out using a portable spirometer
‘‘Vitalograph copd-6’’ apparatus. Expiratory ﬂow-volume
curve was performed for 41 subjects before and 20 min after
inhalation of four puffs of salbutamol (400 lg) metered dose
inhaler (MDI).
The following parameters were obtained:
- Forced expiratory volume in the ﬁrst second (FEV1) as
absolute value and percentage of the predicted value
(FEV1%).
- FEV1%/FVC ratio.
(5) Arterial blood gase analysis
Using blood gas analyzer (ABL-330-Radiometer Copeen-
hagen system) all values were obtained in room air except
for mechanically ventilated patients.
(6) Thoracocentesis and pleural ﬂuid examination
[13] Thoracocentesis and pleural ﬂuid examination were
done for 17 cases, (10 cases of mesothelioma, ﬁve cases of
pneumonia and two cases of bronchogenic carcinoma).
Pleural ﬂuid examination included:
(a) Physical appearance.
(b) Protein level.
(c) Glucose level.
(d) LDH.
(e) Total and differential white blood cell count.
(f) Gram stain.
(g) Z.N. staining.
(h) Culture and sensitivity for aerobic and anaerobic
organisms.
(i) Culture for acid fast bacilli.
(j) Cytological examination.
(7) Blind pleural biopsy by Abram’s needle
It was done for seven cases of mesothelioma according to
the method of James et al. [14].
(8) Fiberoptic bronchoscopy
Fiberoptic bronchoscope was done for 15 cases [15].
It was done using prototype (PENTAX FB-19TV, Japan)
and the following procedures were performed via bronchoscope
- Bronchoalveolar lavage (BAL).
- Endobronchial biopsy.
- Bronchial washing.
- Bronchial brushing.
- Post bronchoscopic sputum cytology.
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(a) Complete blood picture.
(b) Liver function tests (total proteins, albumin, SGOT,
SGPT, and total and direct bilirubin).
(c) Kidney function tests (blood urea and serum creatinine).
(d) Random blood sugar.
(e) Prothrombin time and partial thromplastin time.
(f) The following coagulation markers were evaluated for
all patients at day 1, 2, 3, 4, and 5:
- Soluble ﬁbrin complex (SFMC ELISA kits, MyBioSource
Co., CA, USA) Normal values: – [SFC < 6.25 lg/ml].
- D-dimer. (VIDAS D-Dime Exclusion (DD2)) Normal
values: [D-dimer <500 ng/ml].
- Thrombin antithrombin. (IMUBIND TAT ELISA Assay
Test) normal values: – [TAT < 5.3 ng/mL].
- Antithrombin, (Coamatic Antithro-mbin, Chromogenix,
Molndall, Sweden) normal values: – [antithrombin activity
>70%]
- Protein C. (Corgenix, REAADS Protein C Antigen Test)
normal values: – [Protein C >70%]
- Protein S. (Corgenix, READS protein S Antigen Test kits)
normal values: – [Protein S >50%].
- Fibrinogen (Clauss assay method, Immunospec
Corporation).
Estimation of soluble ﬁbrin monomer complex (SFMC ELISA
kits, MyBioSource co., CA, USA)
Principle of the method
The microtiter plate provided in this kit has been pre-coated
with an antibody speciﬁc to SFMC. Standards or samples
are then added to the appropriate microtiter plate wells with
a biotin-conjugated antibody preparation speciﬁc for SFMC
and Avidin conjugated to Horseradish Peroxidase (HRP) is
added to each microplate well and incubated. Then a TMB
(3,30,5,50 tetramethyl-benzidine) substrate solution is added
to each well. Only those wells that contain SFMC, biotin-
conjugated antibody and enzyme-conjugated Avidin will
exhibit a change in color. The enzyme-substrate reaction is
terminated by the addition of sulfuric acid solution and the
color change is measured spectrophotometrically at a wave-
length of 450 nm ± 2 nm. The concentration of SFMC in
the samples is then determined by comparing the O.D. of the
samples to the standard curve. Cut off value: 6.25 lg/ml.
Estimation of D-dimer (VIDAS D-Dimer Exclusion
(DD2))
Principle of the method
The assay principle combines a two-step enzyme immunoassay
sandwich method with a ﬁnal ﬂuorescent detection (ELFA).
The Solid Phase Receptacle (SPR) serves as the solid phase
with an anti-ﬁbrin degradation product (FbDP) monoclonal
antibody adsorbed on its surface as well as the pipetting device
for the assay. The sample/conjugate mixture is cycled in and
out of the SPR several times to increase the reaction speed.
The antigen binds to antibodies coated on the SPR and to
the conjugate forming a ‘‘sandwich’’. In the second step, the
remaining free antigen sites are saturated by cycling theconjugate in the ﬁfth well of the strip in and out of the SPR.
Unbound components are eliminated during the washing
steps. Cut off value: – 500 ng/ml.
Estimation of thrombin antithrombin (TAT) (IMUBIND
TAT ELISA assay TEST)
Principle of the method
Diluted plasma samples are added to microwells coated with a
monoclonal antibody against thrombin. During an incubation
period, TAT complexes present in the sample will bind to the
antibody coated to the wells. Following a washing step, a bio-
tinylated monoclonal antithrombin III antibody is added to
the microwells and binds to the TAT complexes captured on
the plate during a short incubation period. A streptavidin-
horseradish peroxidase conjugate (SA-HRP) is added to the
microwells to complete the formation of the antibody-enzyme
detection complex. Following another washing step, the addi-
tion of a perborate-3,30-5,50-tetramethylbenzidine (TMB) sub-
strate and its subsequent reaction with the HRP present
generates a blue colored solution. The reaction is stopped by
adding citrate stop solution, which turns the solution color yel-
low. Measuring the solution absorbance a standard curve
determines the level of TAT in the diluted plasma sample. Ex-
pected values: – 1.2–5.3 ng/ml.
Estimation of antithrombin (AT) Activity (COAMATIC
Antithrombin, Chromo-genix, Molndall, Sweden)
Summary and principle of the test
Antithrombin is the most important natural inhibitor of the
coagulation cascade. By inhibiting the coagulation proteases,
especially thrombin, factor Xa, and factor IXa, AT prevents
uncontrolled coagulation and thrombosis. Plasma is incubated
with an excess of factor Xa (FXa) in the presence of heparin.
The residual quantity of FXa is determined by the rate of
hydrolysis of the chromogenic substrate S-2765. The pNA re-
lease measured at 405 nm is inversely proportional to the AT
level in Expected values: >70%in a normal healthy
population.
Estimation of protein C (Corgenix, REAADS Protein C
Antigen Test)
Principle of the test
The protein C Antigen assay is a sandwich ELISA. A capture
antibody speciﬁc for human protein C is coated to 96-microwell
polystyrene plates. Diluted patient plasma is incubated in the
wells, allowing any available protein C to bind to the anti-
human protein C antibody on the microwell surface. Bound
protein C is quantitated using horseradish peroxidase (HRP)
conjugated anti-human Protein C detection antibody. Follow-
ing incubation, unbound conjugate is removed by washing. A
chromogenic substrate of (TMB) and hydrogen peroxide
(H2O2) is added to develop a colored reaction. The intensity
of the color is measured in optical density (O.D.) units with a
spectrophotometer at 450 nm. Protein C antigen relative per-
cent concentrations in patient plasma are determined. Expected
Value: The normal range when normal plasma samples were
tested by REAADS Protein C Antigen assay was 72–160%.
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Test kits)
Principle of the test
The Monoclonal Free Protein S Antigen assay is a sandwich
ELISA. A capture monoclonal antibody speciﬁc for human
Free Protein S is coated to 96-microwell polystyrene plates. Di-
luted patient plasma is incubated in the wells, allowing any
available Free Protein S to bind to the anti-human Free pro-
tein S monoclonal antibody on the microwell surface. Bound
Free Protein S is quantitated using horseradish peroxidase
(HRP) conjugated polyclonal anti-human Protein S detection
antibody. A chromogenic substrate of tetramethyl-benzidine
(TMB) and hydrogen peroxide (H2O2) is added to develop a
colored reaction. The intensity of the color is measured in opti-
cal density (O.D.) units with a spectrophotometer at 450 nm.
Expected values. The normal range for Free Protein S for this
assay is 50–150%.
Estimation of ﬁbrinogen (Clauss assay method, Immunospec
Corporation)
Principle
Immunospec Fibrinogen test kit is based on the Clauss method
of quantifying plasma ﬁbrinogen. The Clauss method mea-
sures the rate of ﬁbrinogen ﬁbrin conversion in the presence
of excess thrombin and has been shown to be rapid, sensitive
and precise. When diluted plasma is clotted with excess throm-
bin, the ﬁbrinogen level is inversely proportional to the clotting
time. A calibration curve is prepared from a ﬁbrinogen refer-
ence and plotted on log–log paper. Expected value range level
in human plasma is considered to be150–400 mg/dl.
Statistical analysis
The demographic, clinical, radiological, physiological and
pathological data gathered together with the patients’ outcome
were tabulated and statistically analyzed and coded, entered
and checked to an Epi-info ﬁle using Epi-info version 10 com-
puter packages. Data were summarized using; the arithmeticTable 1 Demographic data of all studied subjects.
Patients group n= 141
Age (years)
Mean ± SD (range)
52.3 ± 7.9 (33–65)
No %
Gender
Male 81 57.
Female 60 42.
Smoking
Non-smokers 50 35.
Mild-smokers 6 4.
Moderate-smokers 39 27.
Heavy-smokers 46 32.
This table shows that 57.4% of studied patients were males, while 42.6
moderate smokers 27.7% and 4.3% mild smokers. The mean age of studi
In the control group 60% of studied subjects were males and 40% wer
smokers 20% and 8% mild smokers .The mean age of control subjects wmean as an average describing the central tendency of observa-
tions, the standard deviation (SD) as a measure of dispersion
of the results around the mean, the number of observations
for each variable studied (NO). Comparison of means: ANO-
VA and multiple comparison tests (LSD and paired t-test)
were used. For all the above-mentioned statistical tests, the
threshold of signiﬁcance is ﬁxed at the 5% level (p-value), a
p-value P0.05 indicates non-signiﬁcant results, a p-va-
lue < 0.05 indicates signiﬁcant results, a p-value <0.01 indi-
cates high signiﬁcant results, and a p-value <0.001 indicates
very high signiﬁcant results.
Results and discussion
The vast majority (80%) of hospitalized patients with symp-
tomatic venous thromboembolism (VTE) has not undergone
recent surgery. Furthermore, 70–80% of cases of fatal pulmon-
ary embolism (PE) in the hospital occur in medical (non-surgi-
cal) patients. [16]. So, the aim of this study was to assess the
impact of different respiratory insults on blood coagulation.
This study was conducted on 141 patients with different
respiratory disorders, 81 males and 60 females, their ages ran-
ged from 33 to 65 years old with a mean of 52.3 ± 7.9 years.
Twenty-ﬁve apparently healthy control subjects, 15 males
and 10 females, their ages ranged from 23 to 46 years old with
a mean of 35.8 ± 6.76 years were also, included in our study
(Table 1).
Our study included 141 patients with different respiratory
insults (38 COPD patients, bronchial asthma patients were
21, IPF cases were 26, pneumonia cases were 31 and 25 were
malignant diseases) (Table 2).
In the current study, the mean values of SFC, DD and TAT
were higher in patients with positive duplex than negative
duplex and this difference was statistically highly signiﬁcant
while, there was no statistically signiﬁcant difference in the
mean values of other coagulation markers between patients
with positive duplex and negative duplex patients (Table 3).
Also, in the current study, the mean values of SFC, DD and
TAT were higher in positive CT angiography than negative
CT angiography and the difference was statistically highly
signiﬁcant while there was no statistically signiﬁcantControl group n= 25
35.8 ± 6.76 (23–46)
No %
4 15 60
6 10 40
4 14 56
3 2 8
7 5 20
6 4 16
% were females. Non smokers were 35.4%, heavy smokers 32.6%,
ed patients was 52.3 ± 7.9 years and their age range was 33–65 years.
e females. Non smokers were 56%, heavy smokers 16%, moderate
as 35.8 ± 6.76 years and their age range was 23–46 years.
Table 2 Presentation of different diseases in the studied
patients.
Disease Frequency
No %
COPD 38 27
Bronchial asthma 21 14.9
Interstitial pulmonary ﬁbrosis (IPF) 26 18.5
Pneumonia 31 21.9
Malignancy 25 17.7
Lung cancer 15 60
Malignant mesothelioma 10 40
This table shows that COPD patients presented 27% of the studied
patients, while bronchial asthma patients were14.9%, IPF cases
were 18.5%, pneumonia cases were 21.9% and 17.7% were
malignant diseases (60% lung cancer cases and 40% malignant
mesothelioma cases).
336 H.M. Abd Elsalam et al.difference in mean values of other coagulation markers
between patients with positive and negative CT angiography
patients (Table 4).
In agreement with these results, Tsuji et al. [17] found that
the plasma levels of SFC and D-dimer were signiﬁcantly
higher in patients with VTE than patients without VTE.
Soluble ﬁbrin complex and D-dimer are considered as mark-
ers of hyper-coagulable state, as both parameters are reported
to be elevated in DVT [18]. Also LaCapra et al. [19], con-
cluded that, TAT is markedly increased in patients with acute
DVT or PE. As well as, Garcia-Avello et al. [20] studied pa-
tients with acute or subacute lower limb arterial thrombosisTable 3 Levels of different coagulation markers regarding lower li
Values of coagulation markers (Mean ± SD) Positive duplex U.S. (No
Soluble ﬁbrin complex (SFC) 286.4 ± 21.4
D dimmer (DD) 29.5 ± 11.3
Thrombin antithrombin complex (TAT) 17.5 ± 3.8
Antithrombin (AT) 93.5 ± 11.3
Protein C 116 ± 15.6
Protein S 115.5 ± 17.3
Fibrinogen 350.1 ± 44
This table shows that the mean values of SFC, DD and TAT were hig
difference was statistically highly signiﬁcant while there is no statistically s
between both groups.
Table 4 Levels of different coagulation markers in all patients rega
Values of coagulation markers (Mean ± SD) Positive CT angiography (
Soluble ﬁbrin complex (SFC) 292.7 ± 22.4
D dimmer (DD) 715.8 ± 176.4
Thrombin antithrombin complex (TAT) 16.8 ± 4.2
Antithrombin (AT) 98.4 ± 13.5
Protein C 117.99 ± 15.2
Protein S 115.1 ± 17.1
Fibrinogen 347.1 ± 57.7
This table shows that the mean values of SFC, DD and TAT were higher
negative results and the difference was statistically highly signiﬁcant while
coagulation markers between both groups.and found that, there was an elevation of TAT, ﬁbrin mono-
mers and D-dimer levels. In addition to that, Ota et al. [21]
studied suspect patients to have DVT, about 10% of patients
were diagnosed with DVT. He found that, Plasma levels of
D-dimer and SFC in that percentage of patients in whom
DVT were conﬁrmed were signiﬁcantly higher than of those
without DVT.
In the present study, the higher mean values for soluble ﬁ-
brin complex (SFC) were on the third day, while the higher
mean values for both D dimer (DD), thrombin antithrombin
complex (TAT) were on the ﬁfth day, however for antithrom-
bin (AT), protein C and protein S, there were no detectable
variations in their levels on all 5 days (Table 5).
In agreement with these results Nieuwenhuizen et al. [22] re-
ported that, the plasma levels of SFC were signiﬁcantly ele-
vated in patients with thrombosis within a week before its
onset, but the plasma levels of D-dimer, and thrombin anti-
thrombin complex (TAT) were not signiﬁcantly increased
within a week before the onset of thrombosis, thus indicating
that the SFC assay may otherwise be useful for detecting a pre-
thrombotic state and the diagnosis of the prethrombotic state.
With regard to the changes in the levels of D-dimer and SFC,
the plasma levels of D-dimer were further increased after the
onset of DVT, and they were still high at 7 days after its onset,
whereas the plasma SFC levels diminished relatively soon after
development of thrombosis. These ﬁndings suggest that the
SFC reﬂects the early phase of DVT/PE whereas D-dimer
reﬂects the secondary ﬁbrinolysis after clot formation. The
plasma SFC level will decrease 2–3 days after onset of throm-
bosis, but the D-dimer level will not increase immediately after
its onset [43].mb duplex U.S. results in the studied patients.
. 33 cases) Negative Duplex U.S. (No. 108 cases) t p
147.6 ± 86.3 9.12 <0.001
11 ± 19.1 91.61 <0.001
11.2 ± 5.7 5.93 <0.001
99.4 ± 13.9 2.23 >0.05
112.6 ± 14.5 1.62 >0.05
112.7 ± 19.1 0.96 >0.05
326.7 ± 62 4.23 >0.05
her in patients with positive duplex than negative duplex and this
igniﬁcant difference in the mean values of other coagulation markers
rding CT angiography results.
No. 17 cases) Negative CT angiography (No. 124 cases) t p
164.6.2 ± 92.2 5.68 <0.001
352.8 ± 151.6 11.57 <0.001
12.1 ± 5.9 3.18 <0.001
95 ± 13.6 0.98 >0.05
110.8 ± 14 1.81 >0.05
111.4 ± 12.4 0.85 >0.05
321.4 ± 60 4.63 >0.05
in patients having positive CT angiography result than patients with
there was no statistically signiﬁcant difference in mean values of other
Table 5 Comparison between the mean values of different coagulation markers on the ﬁrst 5 days of admission of all studied patients.
Values of coagulation markers (Mean ± SD) Day 1 Day 2 Day 3 Day 4 Day 5
Soluble ﬁbrin complex (SFC) 127.5 ± 65 159.5 ± 83.4 180.1 ± 96.3 145.5 ± 74.3 135.7 ± 69
D-dimer 255.2 ± 113 266.2 ± 9.6 282.2 ± 122 319.5 ± 129.9 437.6 ± 220
Thrombin–antithrombin (TAT) 6.4 ± 2.6 8 ± 3.4 9.4 ± 3.9 10.9 ± 4.6 12.7 ± 5.9
Protein C 117.9 ± 15.2 105.9 ± 17.9 115.9 ± 11.2 111.9 ± 13.4 109.7 ± 10.7
Protein S 114.1 ± 16.6 115.8 ± 17.2 113.8 ± 11.2 118.8 ± 11.4 116.8 ± 10.2
Anti-thrombin(AT) 103.5 ± 13.3 98 ± 13.5 94 ± 10.4 100 ± 13.5 99 ± 10.9
Fibrinogen 296 ± 10.8 298 ± 11 299 ± 12 300.1 ± 59 324.5 ± 60.4
This table shows that the higher mean value for SFC was in the third day of admission, while the higher mean values for DD, TAT and
ﬁbrinogen were on the ﬁfth day. Whereas, there is no detectable variations in levels in of AT, protein C and protein S on all 5 days.
Hypercoagulability in different respiratory diseases 337The concentration of soluble ﬁbrin complex did not
change signiﬁcantly during the initial stage after surgery
(1–2 h), but it increased signiﬁcantly thereafter until day 3,
and then decreased gradually reaching a plateau there after.
On the contrary, the D-dimer increased only slightly after
surgery and remained at low levels during the ﬁrst 3 days,
but it became signiﬁcantly increased from days 5 to 10.
The level of D dimer remained higher than the preoperative
level even on day 14. Thus, the proﬁles of these parameters
related to intravascular thrombus formation are apparently
distinct from one another, most likely reﬂecting different
clinical aspects related to the formation of hemostatic ﬁbrin
clots and their resolution, and also their clearance from the
blood circulation [23].
In the present work, there was a highly statistically signiﬁ-
cant difference in soluble ﬁbrin complex, D-dimer and throm-
bin–antithrombin complex, ﬁbrinogen levels between all
disease groups and the control subjects. The levels of those
markers in bronchial asthma patients were lower than of other
respiratory diseases and control subjects and this difference
was highly statistically signiﬁcant. There was no statistically
signiﬁcant difference between different diseases groups and
control subjects regarding the level of AT, protein C and pro-
tein S (Table 6).
In agreement with the results of this study, Shin [18] found
that, plasma levels of SFC were signiﬁcantly higher in patients
with chronic obstructive pulmonary disease (COPD) than in
control group. Thrombotic complications occurred in patients
with COPD can be explained by increased coagulation due to
Hypoxia which lead to endothelial damage [24]. Thrombin
antithrombin (TAT), which indicates activation of coagulation
system increased signiﬁcantly in COPD patients with PE thanTable 6 Comparison between the levels of coagulation markers am
Values of coagulation markers (Mean ± SD) COPD Asthma
Soluble ﬁbrin complex 179.4 ± 73 6 ± 0.9
D dimer 444 ± 225 354.7 ± 13
Thrombin antithrombin complex 14.3 ± 4.0 1.7 ± 0.8
Fibrinogen 338.6 ± 45 257.6 ± 76
Antithrombin 101.6 ± 13.3 98 ± 14.3
Protein C 108 ± 17.5 115.4 ± 14
Protein S 118.8 ± 20.2 109 ± 16.4
This table shows that, there was highly statistically signiﬁcant difference in
and the control subjects. The levels of such markers in bronchial asthma p
and this difference was highly statistically signiﬁcant. There was no sta
control subjects regarding the levels of AT, protein C and protein S.in those without PE. Moreover, the frequency of PE increased
signiﬁcantly as the TAT level increased and at a level more
than 20 lg/L [42].
Alessandri et al. [25] and Milosz et al. [26] found that, plas-
ma levels of SFC, a marker of thrombin generation, D-dimer,
a marker of in vivo thrombin and plasmin activation, and
ﬁbrinogen when measured in COPD patients compared to
controls matched for sex and age were signiﬁcantly higher in
COPD patients than in healthy subjects. Near similar results
were mentioned by Anetta Undas et al. [27] who studied
COPD patients compared with controls matched for age,
sex, weight and smoking and found that antithrombin, protein
C and protein S did not differ between both groups. The plas-
ma ﬁbrinogen level was studied in patients with chronic
obstructive pulmonary disease and control group, the plasma
ﬁbrinogen level was apparently higher in exacerbated patients
than in control group. The elevated plasma ﬁbrinogen level
may be associated with the hypercoagulability state of chronic
obstructive pulmonary disease and contributes to thrombi in
small pulmonary arteries and arterioles [28].
Psuja et al. [29] found that in severe infection including
community acquired pneumonia, speciﬁc markers of plasma
hypercoagulability, that is, thrombin–antithrombin (TAT)
complexes, prothrombin activating factor F 1 + 2, SFC and
D dimer were all markedly increased. Gouin-Thibault et al.
[30] evaluated the thrombophilic state of different cancer pa-
tients including lung cancer patients, it was found that there
was elevation of clotting factors, such as, ﬁbrinogen/ ﬁbrin
degradation products, hyperﬁbrinogenemia and thrombocyto-
sis and elevation of speciﬁc markers of activation of coagula-
tion such as: ﬁbrinopeptide A, soluble ﬁbrin fragment 1 + 2,
thrombin–antithrombin complexes and D-dimers. [22].ong different respiratory diseases.
IPF Malignancy Pneumonia Control p
201.7 ± 65.3 232.1 ± 46.3 218 ± 75 3.1 ± 0.34* <0.001
3 396.5 ± 206 503.8 ± 199 475 ± 238 *371 ± 72.7 >0.001
14.5 ± 4.3 14.5 ± 3.6 15.17 ± 4.4 *3.6 ± 0.4 >0.001
335.7 ± 60 336.7 ± 40.4 333.4 ± 49 *151.6 ± 4.5 >0.001
97.1 ± 13.9 98.2 ± 13.9 93.8 ± 13.5 100.8 ± 21.1 >0.05
112.7 ± 21 101 ± 12 95 ± 16 112 ± 14.4 >0.05
118 ± 16.9 113.6 ± 12.4 116 ± 16.5 116 ± 16.5 >0.05
SFC, D dimer, TAT and ﬁbrinogen levels between all disease groups
atients were lower than other respiratory diseases and control subjects
tistically signiﬁcant difference between different diseases group and
338 H.M. Abd Elsalam et al.Kubo et al. [31] found that patients with IPF in acute exac-
erbation had elevated plasma level of D-dimer, and the plasma
D-dimer levels in patients who died from acute exacerbations
of IPF were signiﬁcantly higher than those in survivors during
acute exacerbation of IPF.
Jose et al. [7] studied patients with CAP and found that
there is elevated D-dimer level in those patients and that
elevated D-dimer levels were associated with radiologic pneu-
monia extension and poor outcome.
Patients with lung cancer have a higher risk of developing
venous thromboembolism. D-dimer level signiﬁcantly was ele-
vated in those patients. There were no signiﬁcant differences
between males and females. High plasma D-dimer concentra-
tions turned out to be a strong predictor of poor outcome [32].
Suzan Salama et al. [5] concluded that, thrombin anti-
thrombin (TAT), which indicates activation of coagulation
system increased signiﬁcantly in COPD patients with PE thanTable 7 Comparison between the levels of coagulation markers in
Values of coagulation markers (Mean ± SD) Severe COPD (15 pa
Soluble ﬁbrin complex 231.3 ± 5
D dimer 307.2 ± 85.9
Thrombin antithrombin complex 17.3 ± 2.6
Antithrombin 93.7 ± 12.9
Protein C 113.3 ± 16.3
Protein S 115.7 ± 19.8
Fibrinogen 361.5 ± 41
This table shows that the mean values of SFC, DD, TAT and ﬁbrinogen w
and the difference was statistically signiﬁcant, while in AT, Protein C an
Table 8 Comparison between the levels of coagulation markers in
Values of coagulation markers (Mean ± SD) Severe asthma (8 pa
Soluble ﬁbrin complex 6.4 ± 0.6
D dimer 387.8 ± 144
Thrombin antithrombin 1.44 ± 0.8
Antithrombin 99.4 ± 16
Protein C 113.7 ± 15.5
Protein S 122.5 ± 20.7
Fibrinogen 261 ± 62.9
This table shows that there is no statistically signiﬁcant difference in coa
Table 9 Mean values of coagulation markers in lung cancer and m
Values of coagulation markers (Mean ± SD) Lung cancer (15 patie
Soluble ﬁbrin complex 230.1 ± 46.2
D dimer 394 ± 120.7
Thrombin antithrombin 15.4 ± 3.1
Antithrombin 96 ± 13.2
Protein C 115.7 ± 11.2
Protein S 111.3 ± 11.8
Fibrinogen 298.9 ± 44.6
This table shows that there is no signiﬁcant statistical difference in the
malignant mesothelioma cases.in those without PE. Moreover, the frequency of PE increased
signiﬁcantly as the TAT level increases. Eric et al. [8] measured
plasma coagulation markers (D-dimer, antithrombin, factor
IX, and thrombin–antithrombin complex [TAT]) at the time
of presentation of CAP patients to the emergency department
and daily during the ﬁrst week of hospitalization. Coagulation
abnormalities were common, especially for D-dimer and TAT
and concluded that, coagulation abnormalities were common
and persistent in CAP patients. Ferrigno and Bucchen [33]
had found several laboratory abnormalities including pro-
longed and shortened PT and PTT, increased ﬁbrinogen, ﬁbrin
degradation products, TAT, and thrombocytosis in patients
with lung cancer. Wedzicha et al. [34] found that, the mean val-
ues of plasma ﬁbrinogen were elevated in 67 patients of 93
COPD patients with exacerbations. Li Run-ying et al. [35] con-
cluded that, in complicated pneumonia, the values of D-dimer,
ﬁbrinogen increased, and AT decreased gradually. There aremoderate and severe COPD patients.
tients) Moderate COPD (10 patients) t p
101.7 ± 34 6.85 <0.001
198 ± 70 3.34 <0.001
9.2 ± 1 9.4 <0.001
103 ± 10.6 1.89 >0.05
130 ± 14.7 1.55 >0.05
123.5 ± 20.9 0.94 >0.05
297.7 ± 37 3.9 >0.001
ere higher in severe COPD patients than in moderate COPD patients
d Protein S there was no statistically signiﬁcant difference.
moderate and severe bronchial asthma patients.
tients) Moderate asthma (8 patients) t p
5.8 ± 1.1 0.9 >0.05
263.5 ± 110 1.93 >0.05
1.8 ± 0.76 0.97 >0.05
105.1 ± 9.3 0.86 >0.05
117.1 ± 14.9 0.4 >0.05
115 ± 17.5 0.78 >0.05
206.4 ± 69 1.65 >0.05
gulation markers between moderate and severe asthmatic patients.
alignant mesothelioma cases.
nts) Malignant mesothelioma (10 patients) t p
235.2 ± 48.7 0.26 >0.05
352.8 ± 120 0.83 >0.05
13.1 ± 4 1.66 >0.05
101.5 ± 15.3 0.96 >0.05
119.5 ± 17.1 0.58 >0.05
118.0 ± 14.2 0.21 >0.05
314.8 ± 36.8 0.93 >0.05
mean values of all coagulation markers between lung cancer and
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Hypercoagulability in different respiratory diseases 339positive relations between D-dimer and ﬁbrinogen. So, compli-
cated Pneumonia has important impacts on coagulation and
ﬁbrinolysis. Gouin-Thibault et al. [30] evaluated the thrombo-
philic state of different cancer patients including lung cancer
patients; it was found that there was elevation of clotting fac-
tors, such as, ﬁbrinogen/ﬁbrin degradation products, hyperﬁb-
rino-genemia.
The results of this study showed that, the mean values of
coagulation markers SF, DD, TAT and ﬁbrinogen were higher
in sever COPD patients than in moderate COPD patients and
the difference was of high statistical signiﬁcance, while regard-
ing the levels of AT, Protein S and Protein C there were no sta-
tistically signiﬁcant difference (Tables 7 and 8).
Gunen et al. [36] found that the VTE increased with the
increasing severity of COPD as it was higher in stage IV sever-
ity than other stages and also, with increased severity of exac-
erbation. Sheng-chen et al. [37] investigated patients with acute
exacerbations of COPD in the respiratory intensive care unit
and found that the DVT prevalence was 10.7% by ultrasonog-
raphy. DVT and PE were more likely in the setting of severe
decompensated COPD.
The results of the current work showed that, there was no
statistically signiﬁcant difference in the mean values of all
coagulation markers between mesothelioma and bronchogenic
carcinoma (Table 9). In agreement with these results Golden-
berg et al. [38] stated that, there was no statistically signiﬁcant
difference in the level of coagulation markers between lung
carcinoma and malignant mesothelioma.
Our results show that the mean values of SFC and D dimer
were higher in both mechanically ventilated COPD and pneu-
monia patients than non mechanically ventilated patients,
while the difference was statistically not signiﬁcant between
mechanically ventilated and non mechanically ventilated pa-
tients with bronchial asthma, IPF and malignant patients (Ta-
ble 10). In agreement with our results, Feng Yan et al. [39]
found that the levels of D-dimer and ﬁbrinogen were signiﬁ-
cantly increased in COPD ventilated group compared with
non ventilated group. So, he concluded that, prethrombotic
state exists in mechanically ventilated COPD patients and
aggressive anticoagulation therapy, can shorten the time of
weaning and reduce the mortality in these patients. Guneysel
et al. [40] showed that plasma D-dimer level is increased signif-
icantly in CAP group compared to control group. Also the D-
dimer level increases proportionally with the severity of CAP
including patients who were mechanically ventilated. This con-
dition supports the relationship between D-dimer level and the
severity of CAP.Conclusions
Common respiratory disorders especially, COPD exacerba-
tions, pneumonia, interstitial pulmonary ﬁbrosis and lung can-
cer are associated with an increased risk of the development of
venous thromboembolism.
Early detection of soluble ﬁbrin complex, thrombin anti-
thrombin complex, D dimer and ﬁbrinogen may be useful
for the identiﬁcation of the prethrombotic state which may
help to prevent the onset of thrombotic disorders such as deep
venous thrombosis, pulmonary embolism and disseminated
intravascular coagulation and thereby improve the outcome
of various respiratory diseases.
340 H.M. Abd Elsalam et al.Recommendations
Identifying medical patients with different respiratory diseases
at risk of venous thromboembolism and providing effective
anticoagulant prophylaxis is an important health care priority
to reduce the burden of this morbid and sometimes fatal
disease.
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